Identifying MicroRNAs Regulating B7-H3 in Breast Cancer: the Clinical Impact of MicroRNA-29c

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Mar 1

PMID 24577056

Citations 67

Authors

M K Nygren

C Tekle

V A Ingebrigtsen

R Makela

M Krohn

M R Aure

C E Nunes-Xavier

M Perala

T Tramm

J Alsner

J Overgaard

J M Nesland

E Borgen

A-L Borresen-Dale

O Fodstad

K K Sahlberg

S-K Leivonen

Affiliations

Soon will be listed here.

Abstract

Background: B7-H3, an immunoregulatory protein, is overexpressed in several cancers and is often associated with metastasis and poor prognosis. Here, our aim was to identify microRNAs (miRNAs) regulating B7-H3 and assess their potential prognostic implications in breast cancer.

Methods: MicroRNAs targeting B7-H3 were identified by transfecting two breast cancer cell lines with a library of 810 miRNA mimics and quantifying changes of B7-H3 protein levels using protein lysate microarrays. For validations we used western immunoblotting and 3'-UTR luciferase assays. Clinical significance of the miRNAs was assayed by analysing whether their expression levels correlated with outcome in two cohorts of breast cancer patients (142 and 81 patients).

Results: We identified nearly 50 miRNAs that downregulated B7-H3 protein levels. Western immunoblotting validated the impact of the 20 most effective miRNAs. Thirteen miRNAs (miR-214, miR-363*, miR-326, miR-940, miR-29c, miR-665, miR-34b*, miR-708, miR-601, miR-124a, miR-380-5p, miR-885-3p, and miR-593) targeted B7-H3 directly by binding to its 3'-UTR region. Finally, high expression of miR-29c was associated with a significant reduced risk of dying from breast cancer in both cohorts.

Conclusions: We identified miRNAs efficiently downregulating B7-H3 expression. The expression of miR-29c correlated with survival in breast cancer patients, suggesting a tumour suppressive role for this miRNA.

Citing Articles

Recent insights and perspectives into the role of the miRNA‑29 family in innate immunity (Review).

Yao X, Wu J, Yuan S, Yuan F Int J Mol Med. 2025; 55(3).

PMID: 39886977 PMC: 11781520. DOI: 10.3892/ijmm.2025.5494.

Altered Atlas of Exercise-Responsive MicroRNAs Revealing miR-29a-3p Attacks Armored and Cold Tumors and Boosts Anti-B7-H3 Therapy.

Mei J, Luo Z, Cai Y, Wan R, Qian Z, Chu J Research (Wash D C). 2025; 8():0590.

PMID: 39845707 PMC: 11751204. DOI: 10.34133/research.0590.

B7-H3 in glioblastoma and beyond: significance and therapeutic strategies.

Babic D, Jovcevska I, Zottel A Front Immunol. 2024; 15():1495283.

PMID: 39664380 PMC: 11632391. DOI: 10.3389/fimmu.2024.1495283.

A promising target for breast cancer: B7-H3.

Jiang Y, Liu J, Chen L, Qian Z, Zhang Y BMC Cancer. 2024; 24(1):182.

PMID: 38326735 PMC: 10848367. DOI: 10.1186/s12885-024-11933-3.

Soluble B7-H3 in Colorectal Cancer.

Kovaleva O, Gratchev A, Sokolov N, Maslennikov V, Kuzmin Y, Gershtein E Bull Exp Biol Med. 2023; 176(1):87-90.

PMID: 38085395 DOI: 10.1007/s10517-023-05972-2.

References

Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J . B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011; 186(3):1093-9. DOI: 10.1016/j.juro.2011.04.103. View

Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View

Betel D, Wilson M, Gabow A, Marks D, Sander C . The microRNA.org resource: targets and expression. Nucleic Acids Res. 2007; 36(Database issue):D149-53. PMC: 2238905. DOI: 10.1093/nar/gkm995. View

Ambros V . microRNAs: tiny regulators with great potential. Cell. 2002; 107(7):823-6. DOI: 10.1016/s0092-8674(01)00616-x. View

Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y . MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 2011; 71(19):6208-19. PMC: 3940359. DOI: 10.1158/0008-5472.CAN-11-0073. View

Xu H, Cheung I, Guo H, Cheung N . MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009; 69(15):6275-81. PMC: 2719680. DOI: 10.1158/0008-5472.CAN-08-4517. View

Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z . Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012; 7(4):e34210. PMC: 3327688. DOI: 10.1371/journal.pone.0034210. View

Zhao J, Lin J, Lwin T, Yang H, Guo J, Kong W . microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood. 2010; 115(13):2630-9. PMC: 2852365. DOI: 10.1182/blood-2009-09-243147. View

Wang J, Chong K, Nakamura Y, Nguyen L, Huang S, Kuo C . B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol. 2013; 133(8):2050-8. PMC: 3760237. DOI: 10.1038/jid.2013.114. View

10.

Roth T, Sheinin Y, Lohse C, Kuntz S, Frigola X, Inman B . B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007; 67(16):7893-900. DOI: 10.1158/0008-5472.CAN-07-1068. View

11.

Zang X, Sullivan P, Soslow R, Waitz R, Reuter V, Wilton A . Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010; 23(8):1104-12. PMC: 2976590. DOI: 10.1038/modpathol.2010.95. View

12.

Orom U, Nielsen F, Lund A . MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008; 30(4):460-71. DOI: 10.1016/j.molcel.2008.05.001. View

13.

Presneau N, Eskandarpour M, Shemais T, Henderson S, Halai D, Tirabosco R . MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Br J Cancer. 2012; 108(4):964-72. PMC: 3590650. DOI: 10.1038/bjc.2012.518. View

14.

Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S . MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012; 26(9):2011-8. DOI: 10.1038/leu.2012.90. View

15.

Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland J, Qvist H . Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003; 21(18):3469-78. DOI: 10.1200/JCO.2003.02.009. View

16.

Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P . MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012; 7:31. PMC: 3349474. DOI: 10.1186/1746-1596-7-31. View

17.

Leivonen S, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K . Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009; 28(44):3926-36. DOI: 10.1038/onc.2009.241. View

18.

Majid S, Dar A, Saini S, Shahryari V, Arora S, Zaman M . miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2012; 19(1):73-84. PMC: 3910324. DOI: 10.1158/1078-0432.CCR-12-2952. View

19.

Grimson A, Farh K, Johnston W, Garrett-Engele P, Lim L, Bartel D . MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27(1):91-105. PMC: 3800283. DOI: 10.1016/j.molcel.2007.06.017. View

20.

Leivonen S, Sahlberg K, Makela R, Due E, Kallioniemi O, Borresen-Dale A . High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 2013; 8(1):93-104. PMC: 5528509. DOI: 10.1016/j.molonc.2013.10.001. View